Phibro Animal Health Co. Expected to Post FY2024 Earnings of $1.13 Per Share (NASDAQ:PAHC)

Phibro Animal Health Co. (NASDAQ:PAHC - Free Report) - Zacks Research boosted their FY2024 earnings estimates for shares of Phibro Animal Health in a report released on Tuesday, April 23rd. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.13 for the year, up from their prior estimate of $1.12. The consensus estimate for Phibro Animal Health's current full-year earnings is $1.12 per share. Zacks Research also issued estimates for Phibro Animal Health's Q4 2024 earnings at $0.37 EPS, Q2 2025 earnings at $0.34 EPS, Q4 2025 earnings at $0.40 EPS, FY2025 earnings at $1.21 EPS and Q3 2026 earnings at $0.32 EPS.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $0.33 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.06. Phibro Animal Health had a net margin of 1.51% and a return on equity of 16.67%. The firm had revenue of $249.90 million during the quarter, compared to analyst estimates of $242.91 million.

Separately, StockNews.com upgraded shares of Phibro Animal Health from a "hold" rating to a "buy" rating in a research report on Tuesday, April 9th.

Phibro Animal Health Trading Down 7.7 %

Phibro Animal Health stock traded down $1.05 during midday trading on Wednesday, reaching $12.56. The stock had a trading volume of 111,186 shares, compared to its average volume of 141,573. Phibro Animal Health has a twelve month low of $9.40 and a twelve month high of $15.96. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.12 and a quick ratio of 1.60. The firm has a market cap of $508.72 million, a price-to-earnings ratio of 34.89, a PEG ratio of 4.83 and a beta of 0.75. The firm's fifty day simple moving average is $12.80 and its two-hundred day simple moving average is $11.76.

Institutional Investors Weigh In On Phibro Animal Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC raised its holdings in shares of Phibro Animal Health by 59.8% during the 3rd quarter. Barclays PLC now owns 35,638 shares of the company's stock valued at $456,000 after purchasing an additional 13,332 shares in the last quarter. Trexquant Investment LP raised its holdings in shares of Phibro Animal Health by 143.6% during the 3rd quarter. Trexquant Investment LP now owns 35,872 shares of the company's stock valued at $458,000 after purchasing an additional 21,147 shares in the last quarter. Brandes Investment Partners LP raised its holdings in shares of Phibro Animal Health by 38.5% during the 3rd quarter. Brandes Investment Partners LP now owns 1,873,300 shares of the company's stock valued at $23,922,000 after purchasing an additional 520,697 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Phibro Animal Health by 358.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,357 shares of the company's stock valued at $27,000 after purchasing an additional 1,843 shares in the last quarter. Finally, New York State Common Retirement Fund raised its holdings in shares of Phibro Animal Health by 20.9% during the 3rd quarter. New York State Common Retirement Fund now owns 69,944 shares of the company's stock valued at $893,000 after purchasing an additional 12,110 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company's stock.

Phibro Animal Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, March 27th. Shareholders of record on Wednesday, March 6th were given a $0.12 dividend. The ex-dividend date was Tuesday, March 5th. This represents a $0.48 dividend on an annualized basis and a yield of 3.82%. Phibro Animal Health's payout ratio is 133.33%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.